Vetoquinol falls on lower H1 EBITDA, US market troubles

Vetoquinol SA

13/09/2024 09:33

** Shares in French animal health company Vetoquinol
 VETO.PA  fall 8% after it reported a lower H1 EBITDA, citing a
drop in business in the U.S. and higher R&D spending
    ** Midcap Partners highlights a 24.6% decrease in EBITDA,
reflecting the company's U.S. situation and increased R&D
expenses by 21% year-on-year
    ** Portzamparc analysts point to "significantly lower
results" and cut their top line scenario from +5% to 3.5% on a
like-for-like basis, noting the group may find it difficult to
recover market shares lost in H1 in the U.S.
    ** Share on track for its worst day since Sept. 16, 2022,
when it closed 17.9% lower
    ** Out of five analysts covering Vetoquinol, three rate the
stock as "strong buy" or "buy," two rate it as "hold" and none
rate it as "strong sell" or "sell"

 (Reporting by Leo Marchandon)
 ((Leo.marchandon@thomsonreuters.com))